RG-II from Panax ginseng C.A. Meyer suppresses asthmatic reaction

In Duk Jung1,2,#, Hye Young Kim3,#, Jin Wook Park1, Chang-Min Lee1, Kyung Tae Noh1, Hyun Kyu Kang1, Deok Rim Heo1, Su Jung Lee1, Kwang Hee Son1, Hee-ju Park1, Sung Jae Shin4, Jong-Hwan Park5, Seung-Wook Ryu1, Jong Keun Seo7 & Yeong-Min Park1,2,*

1Department of Microbiology and Immunology, School of Medicine, Pusan National University, 2Research Institute of Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan 626-770, 3Department of Pediatrics, Pusan National University Hospital, Pusan 602-739, 4Department of Microbiology, College of Medicine, Chungnam National University, Daejeon 301-747, 5Department of Biochemistry, College of Medicine, Konyang University, Daejeon 302-711, 6Cell Signaling and Bioimaging Laboratory, Department of Bio and Brain Engineering, KAIST, Daejeon 305-701, Korea

In asthma, T helper 2 (Th2)-type cytokines such as interleukin (IL)-4, IL-5, and IL-13 are produced by activated CD4+ T cells. Dendritic cells played an important role in determining the fate of naïve T cells into either Th1 or Th2 cells. We determined whether RG-II regulates the Th1/Th2 immune response by using an ovalbumin-induced murine model of asthma. RG-II reduced IL-4 production but increased interferon-gamma production, and inhibited GATA-3 gene expression. RG-II also inhibited asthmatic reactions including an increase in the number of eosinophils in bronchoalveolar lavage fluid, an increase in inflammatory cell infiltration in lung tissues, airway luminal narrowing, and airway hyperresponsiveness. This study provides evidence that RG-II plays a critical role in ameliorating the pathogenic process of asthmatic inflammation in mice. These findings provide new insights into the immunotherapeutic role of RG-II in terms of its effects in a murine model of asthma. [BMB reports 2012; 45(2): 79-84]

INTRODUCTION

Asthma is a chronic inflammatory disease affecting the airways that is characterized by recurring symptoms, including reversible airflow obstruction and bronchospasm (1). Asthma episodes are thought to be caused by a combination of genetic and environmental factors such as allergens, tobacco smoke, and emotional stress (2, 3). As a model, ovalbumin (OVA)-induced asthma is characterized by airway hyperresponsiveness (AHR) and airway inflammation (4), and is closely associated with the accumulation of eosinophils, neutrophils, and lymphocytes in the bronchial lumen and lung tissues (4). These cellular infiltrates release various chemical mediators capable of inducing AHR (5, 6). Additionally, recruitment of these inflammatory cells from the blood to sites of inflammation is regarded as a central event in the development and prolongation of airway inflammation (7).

The roots of Panax ginseng are precious since the plant requires 4–6 years to harvest, whereas the leaves can be harvested every year. If the leaves of Panax ginseng had similar pharmacological activity as the roots, much more of the therapeutic compounds could be available for clinical use. Previous studies have reported that polysaccharides from the leaves of Panax ginseng possess potent anti-complementary (8) and anti-ulcer activities (9), indicating the potential clinical value of the leaves.

Antigen-activated CD4+ T cells are able to differentiate into different types of effector cells, each with distinct functional properties conferred by cytokines (10, 11). The helper 2 (Th2)-type cytokines interleukin-4 (IL-4), IL-5, and IL-13, all of which are expressed by activated CD4+ T cells, have critical roles in the pathogenesis of asthma by controlling immunoglobulin E (IgE) production, mast cell growth, as well as differentiation and activation of mast cells and eosinophils (12, 13). In contrast, Th1 cytokines such as interferon-gamma (IFN-γ) and IL-12, which downregulate the Th2 response, inhibit the development of allergic lung inflammation (14, 15). Therefore, therapeutic interventions that simultaneously inhibit Th2 cytokine production while enhancing Th1 cytokine production may be useful in treating allergic asthma (16).

GATA-3, a member of the GATA family of transcription factors, is a transcription factor that binds to the T cell receptor-alpha (TCR-α) gene enhancer (17). Specifically, GATA-3 is induced through the action of the STAT6 protein upon
Inhibition of asthmatic reactions by RG-II

In Duk Jung, et al.

In Duk Jung, et al.

In this study, administration of RG-II before the final airway OVA challenge resulted in significant inhibition of asthmatic reactions, suggesting that RG-II could play a critical role in the improvement of the pathogenic processes of asthma in mice.

RESULTS

RG-II inhibits AHR, lung inflammation, and inflammatory cell infiltration

Airway responsiveness was measured as a Penh value in response to increasing doses of methacholine. In OVA-sensitized and -challenged mice, the dose-response curve of the Penh value was shifted to the left compared to that of control mice (Fig. 1A). In addition, the Penh value produced by methacholine administration (at doses ranging from 2.5-50 mg/ml) was significantly higher in the OVA-sensitized and -challenged mice compared to controls. In OVA-sensitized and -challenged mice treated with RG-II, the dose-response curve of the Penh value was shifted to the right compared to that of untreated OVA-sensitized and -challenged mice. Moreover, the shift was dose-dependent.

Histological analyses revealed the typical pathological features of asthma in OVA-exposed mice compared to control mice, with the OVA-exposed mice displaying numerous inflammatory cells, including infiltrated eosinophils around the bronchioles (Fig. 1B). Mice treated with RG-II showed a marked decrease in inflammatory cell infiltration in the peribronchiolar and perivascular regions (Fig. 1B). Therefore, the increases in total lung inflammation and cell infiltration were significantly inhibited by administration of RG-II. These results suggest that RG-II inhibits OVA-induced airway hyperresponsiveness and antigen-induced inflammation in the lungs, including the influx of eosinophils.

RG-II reduces Th2 cytokine levels in lung tissues of OVA-sensitized and -challenged mice

BAL fluids were obtained 24 hours after the final challenge in saline-inhaled mice administered PBS (CON), OVA-sensitized mice administered saline (OVA), and OVA-sensitized mice administered a high dose of RG-II (100 mg/kg, RG-II/H). Airway responsiveness to aerosolized methacholine was measured in restrained and conscious mice. Mice placed into the main chamber and nebulized first with PBS, followed by increasing doses (2.5 to 50 mg/ml) of methacholine for 15 min for each nebulization, during which Penh values were determined. (B) Mice were sensitized and challenged as described above. Sections were obtained from the lungs of mice receiving control (CON), OVA (OVA), OVA plus a low dose of RG-II (RG-II/L), and OVA plus a high dose of RG-II (RG-II/H). Sections were stained by haematoxylin and eosin, PAS, and Alcian blue (400×).

Fig. 1. Effect of RG-II on airway responsiveness, lung inflammation, and inflammatory cell infiltration in OVA-treated mice. (A) Airway responsiveness was measured 24 hours after the final challenge in saline-inhaled mice administered PBS (CON), OVA-sensitized mice administered saline (OVA), OVA-sensitized mice administered a low dose of RG-II (20 mg/kg, RG-II/L), and OVA-sensitized mice administered a high dose of RG-II (100 mg/kg, RG-II/H). Airway responsiveness to aerosolized methacholine was measured in unrestrained and conscious mice. Mice were placed into the main chamber and nebulized first with PBS, followed by increasing doses (2.5 to 50 mg/ml) of methacholine for 15 min for each nebulization. Readings of breathing parameters were taken for 3 minutes after each nebulization, during which Penh values were determined. (B) Mice were sensitized and challenged as described above. Sections were obtained from the lungs of mice receiving control (CON), OVA (OVA), OVA plus a low dose of RG-II (RG-II/L), and OVA plus a high dose of RG-II (RG-II/H). Sections were stained by haematoxylin and eosin, PAS, and Alcian blue (400×).
RG-II decreases IgE levels in the serum and the number of inflammatory cells in BAL fluid

Since Th2 cytokines promote airway inflammation in asthma by increasing IgE levels, which in turn favors the Th2 inflammatory pathway, we measured how much RG-II modulates serum IgE levels in OVA-induced mice. As shown in Fig. 3, serum IgE levels in OVA-induced mice were significantly higher compared to those in control mice. RG-II significantly decreased serum IgE levels (Fig. 3A), but not serum IgG2a levels (Fig. 3B). These data indicate that RG-II modulates the Th1/Th2 balance towards Th1 in an OVA-induced asthma model. The numbers of total cells, eosinophils, lymphocytes, and macrophages in BAL fluid increased significantly 24 hours after OVA challenge compared to the numbers of cells after saline inhalation (Fig. 3C). These increases in the numbers of inflammatory cells were significantly inhibited by RG-II administration.

RG-II reduces GATA-3 expression in lung tissues of OVA-sensitized and challenged mice

Western blot analysis showed that GATA-3 and T-bet expression was significantly increased in lung tissues 24 hours after OVA challenge compared to control tissues. Administration of RG-II significantly inhibited this increase in GATA-3 expression (Fig. 4A). On the other hand, RG-II administration induced an increase in T-bet expression (Fig. 4B).

**DISCUSSION**

This is first study to demonstrate that RG-II ameliorates airway inflammation in a murine model of asthma. Notably, RG-II profoundly inhibited asthmatic reactions, including leukocyte recruitment into the airway and lung inflammation. We also observed that RG-II regulates the Th1/Th2 balance by mediating the levels of T-bet and GATA3.

OVA-induced asthma is recognized as a disease caused by chronic airway inflammation, which is characteristically associated with the infiltration of lymphocytes, eosinophils, and neutrophils into the bronchial lumen. Presently, we observed that OVA-induced asthma increased eosinophil infiltration, thickness of the bronchial wall, and surface area of smooth muscle. However, these events were significantly inhibited by administration of RG-II. T-bet, a member of the T-box family of transcription factors, is a master determinant of the Th1 cell lineage (20, 21). Indeed, T-bet-deficient mice lack the Th1 immune response (22), which inhibits allergic responses (23, 24). Moreover, ectopic expression of T-bet in murine Th2 cells directs activation of IFN-γ as well as upregulation of IL-12Rβ (25, 26). On the other hand, GATA-3 belongs to the GATA family of transcription factors. Six members (GATA-1 to GATA-6) of this family have been identified in birds, and homologues have been found in both mammals and birds. Based on their expression profiles and structures, GATA proteins may be classified as either hematopoietic (GATA-1 to GATA-3) (27) or non-hematopoietic (GATA-4 to GATA-6). Naïve CD4+ T cells express low levels of GATA-3. However, the expression of GATA-3 is dependent upon T cell lineage; it is markedly upregulated in cells differentiating along the Th2 pathway, whereas it is downregulated in cells differentiating along the Th1 pathway (28). These data demonstrate that RG-II inhibits the increase in GATA3 expression in OVA-sensitized and OVA-challenged mice (Fig. 4). Therefore, we can conclude that RG-II ad-
Inhibition of asthmatic reactions by RG-II
In Duk Jung, et al.

Fig. 3. Effect of RG-II on IgE and IgG2a levels in serum of OVA-treated mice and the number of total cells and different cell types in BAL fluids of OVA-treated mice. Blood was collected by cardiac puncture, and serum IgE (A) and IgG2a (B) levels were measured. IgE and IgG2a levels were analyzed by using ELISA (n=5). (C) Mice were sensitized with OVA on days 0 and 14 by i.p. injection of OVA emulsified in 1 mg of aluminum hydroxide. Three days later, mice were treated with vehicle (CON), OVA (OVA), OVA plus a low dose of RG-II (20 mg/kg, RG-II/L), or OVA plus a high dose of RG-II (100 mg/kg, RG-II/H). The mice were challenged for 30 minutes with a 5% (w/v) OVA aerosol in saline (or saline alone as a control) using an ultrasonic nebulizer. The BAL cells were collected 24 hours after OVA challenge. The results shown are from a single representative experiment of the total five experiments performed.

MATERIALS AND METHODS

Mice
Female, 6 to 8-week-old, BALB/c mice that were certified free of murine-specific pathogens were obtained from Charles River Laboratories (Yokohama, Japan). All experimental animals were maintained under a protocol approved by the Institutional Animal Care and Use Committee of Pusan National University Medical School.

Purification of RG-II
A crude polysaccharide fraction (GL-2) was prepared from the leaves of Panax ginseng by hot water extraction, ethanol precipitation, and dialysis (B). GL-2 was fractionated by a Cetavlon (cetyltrimethylammonium bromide) precipitation, and a weakly acidic polysaccharide fraction (GL-4) was obtained. The Fc receptor expression-enhancing polysaccharide (RG-II) was purified from GL-4 by anion-exchange chromatography on DEAE Sepharose CL-6B as described previously (30). To remove the colored materials in the polysaccharide, RG-II was further purified on a Q-Sepharose column (C1-form). For this, the column was washed with water and eluted sequentially with 0.1, 0.2, 0.3, 0.4, 0.5, and 1.0 M NaCl. The major fraction, which was eluted with 0.3 M NaCl, was further fractionated by gel filtration on a Bio-Gel P-30 column to obtain the purified GL-4IIb2 (yield: 5.8 mg/kg dry leaves).

Experimental protocol
Mice were sensitized intraperitoneally (i.p.) with 20 μg of OVA (Sigma-Aldrich, St. Louis, MO, USA) emulsified in 25 μl of aluminum hydroxide (Pierce, Rockford, IL, USA) on days 0 and 14. Mice were challenged for 30 min with OVA (5%) via the airway from days 20 to 22. Bronchoalveolar lavage (BAL) fluid was obtained 24 hours after the final challenge. At the time of lavage, the mice (five mice from each group) were killed using an overdose of ether. The chest cavity was exposed to allow expansion, after which the trachea was carefully incised and the catheter secured with ligatures. Pre-warmed saline solution was then slowly infused into the lungs and withdrawn. The aliquots were pooled and stored at 4°C. A portion of each pooled aliquot was then centrifuged, and the supernatants were kept at −70°C until use.

Administration of RG-II
Female BALB/c mice were injected i.p. with 20 mg/kg/day or 100 mg/kg/day of RG-II (in a 200 μl volume) everyday from days 17 to 19.

Total cell counting
Total cell numbers were counted with a hemocytometer. Smears of BAL cells prepared with CytoSpin II (Shandon, Runcorn, UK) were stained with Diff-Quick solution (Merck, Darmstadt, Germany) for differential cell counting. Two independent and blinded investigators counted the cells using a microscope. Approximately 200 cells were counted in each of
four random locations.

**Immunohistochemistry**

Twenty-four hours after the final challenge, lungs were removed from the mice following sacrifice. Prior to lung removal, the lungs and trachea were filled by intratracheal administration of a fixative (4% paraformaldehyde) using a liguature around the trachea. Lung tissues were then fixed with 10% (v/v) paraformaldehyde. The specimens were dehydrated and embedded in paraffin. For histological examination, 4 μm-thick sections of fixed and embedded tissues were cut on a Leica model 2165 rotary microtome (Leica, Nussloch, Germany), placed on glass slides, deparaffinized, and sequentially stained with hematoxylin 2 and eosin-Y (Richard-Allan Scientific, Kalamazoo, MI, USA). To identify mucus-producing cells, lung sections were stained with periodic acid-Schiff (PAS) and Alcian blue (AB).

**Determination of airway responsiveness to methacholine**

Airway responsiveness in mice was measured 24 hours after the final challenge in an unrestrained conscious state, as previously described (9). Mice were placed in a barometric plethysmographic chamber (All Medicus, Seoul, Korea), and baseline readings were taken for 3 minutes and then averaged. Aerosolized methacholine at various concentrations (2.5 to 50 mg/ml) was nebulized through an inlet of the main chamber. Enhanced pause (Penh), which was calculated according to the manufacturer’s protocol as (expiratory time/relaxation time-1) × (peak expiratory flow/peak inspiratory flow), is a dimensionless value that is a function of the proportion of maximal expiratory to maximal inspiratory box pressure signals and a function of the timing of expiration. In this study, Penh was used as a measure of airway responsiveness to methacholine. Results are expressed as the percent increase in Penh following challenge with each concentration of methacholine, and the baseline Penh (after saline challenge) was set to 100%. Penh values taken for 3 minutes following each nebulization were averaged and evaluated.

**Measurement of cytokines**

Cytokine levels in BAL fluid were determined by enzyme-linked immunosorbent assay (ELISA). ELISA kits from R&D Systems (Minneapolis, MN, USA) were employed for the measurement of IL-4, IL-5, IL-13, IL-12, and IFN-γ.

**Western blot analysis**

The lung tissues were homogenized, washed with phosphate-buffered saline (PBS), and incubated in lysis buffer containing a protease inhibitor cocktail (Sigma-Aldrich) to obtain extracts of lung and spleen proteins. The samples were loaded onto 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels and the separated proteins were electrotransferred to polyvinylidene difluoride membranes. The blots were incubated with anti-GATA-3 antibody or anti-T-bet antibody overnight at 4°C. After washing, the blots were next incubated with horseradish peroxidase-conjugated secondary antibody. Following three washes with Tris-buffered saline containing Tween-20, immunoreactive bands were visualized using an enhanced chemiluminescence detection system.

**Measurement of OVA-specific serum IgE levels**

OVA-specific serum IgE levels were determined in samples collected 24 hours after the final OVA challenge using ELISA. Briefly, a 96-well microtiter plate was coated with OVA (10 mg/ml), followed by incubation with mouse sera and then biotin-conjugated rat anti-mouse IgE (Pharmingen, San Diego, CA, USA). Then, avidin-horseradish peroxidase solution was added to each well. Units are shown as optical density readings at 405 nm.

**Acknowledgements**

This study was financially supported by the [2010 Post-Doc. Development Program] of Pusan National University and by a grant of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A111025-1101-0000100).

**REFERENCES**


